厄贝沙坦氢氯噻嗪联合美托洛尔治疗重症心力衰竭的临床效果分析

Clinical effect analysis of irbesartan hydrochlorothiazide combined with metoprolol in the treatment of severe heart failure

目的:分析厄贝沙坦氢氯噻嗪联合美托洛尔治疗重症心力衰竭的应用价值。方法:2020年1-12月收治重症心力衰竭患者126例,随机分为两组,各63例。对照组给予厄贝沙坦氢氯噻嗪治疗;研究组在厄贝沙坦氢氯噻嗪基础上给予美托洛尔联合治疗。比较两组治疗效果。结果:研究组治疗后心排血量、左室短轴缩短率、左室射血分数及每分钟搏出量均高于对照组,差异有统计学意义(P<0.05);研究组心功能降低1级时间、心力衰竭纠正时间及住院时间均低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:对重症心力衰竭患者实施厄贝沙坦氢氯噻嗪联合美托洛尔治疗,能够有效改善患者临床症状,缩短住院时间,且安全性较高。

Objective:To analyze the application value of irbesartan hydrochlorothiazide combined with metoprolol in the treatment of severe heart failure.Methods:From January to December 2020,126 patients with severe heart failure were selected,they were randomly divided into the two groups with 63 cases in each group.The control group was treated with irbesartan hydrochlorothiazide.The study group was given metoprolol combined therapy on the basis of irbesartan hydrochlorothiazide.We compared the treatment effects of the two groups.Results:The cardiac output,left ventricular short axis shortening rate,left ventricular ejection fraction and stroke volume per minute and other cardiac function indexes after treatment in the study group were higher than those of the control group,the differences were statistically significant(P<0.05).The time of grade 1 reduction of cardiac function,heart failure correction time and hospital stay in the study group were lower than those in the control group,the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Using irbesartan hydrochlorothiazide combined with metoprolol in the treatment of patients with severe heart failure can effectively improve the clinical symptoms of patients,shorten the length of hospitalization,and has high safety.